Evogene Ltd. (NASDAQ:EVGN) Short Interest Down 81.9% in July

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant drop in short interest in July. As of July 31st, there was short interest totaling 45,127 shares, a drop of 81.9% from the July 15th total of 248,770 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average trading volume of 210,507 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Evogene Stock Performance

EVGN opened at $0.70 on Wednesday. Evogene has a one year low of $0.37 and a one year high of $1.50. The company has a market cap of $6.11 million, a P/E ratio of -0.50 and a beta of 1.40. The business’s 50-day simple moving average is $0.53 and its 200-day simple moving average is $0.73.

Evogene (NASDAQ:EVGN) last posted its earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.33). The business had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.35 million. Evogene had a negative return on equity of 158.82% and a negative net margin of 638.12%.

Institutional Trading of Evogene

Several institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC lifted its position in Evogene by 169.4% in the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 36,206 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Evogene during the fourth quarter worth about $25,000. Finally, Jane Street Group LLC increased its position in shares of Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,387 shares in the last quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.